Accord BioPharma’s Biosimilar IMULDOSA gains USFDA approval for treatment of chronic inflammatory conditions Read more
Novel therapies to drive Crohn’s disease market growth across 8MM to $15 bn by 2032: GlobalData Read more
Crohn’s disease treatment market sees major shift with biosimilars and next-gen therapies: GlobalData Read more